视网膜革命：信号通路疗法、基因疗法、线粒体疗法、人工智能。
The retina revolution: signaling pathway therapies, genetic therapies, mitochondrial therapies, artificial intelligence.
机构信息
Department of Ophthalmology, Byers Eye Institute, Horngren Family Vitreoretinal Center, Stanford University School of Medicine, Palo Alto, California.
Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.
出版信息
Curr Opin Ophthalmol. 2020 May;31(3):207-214. doi: 10.1097/ICU.0000000000000656.
PURPOSE OF REVIEW
The aim of this article is to review and discuss the history, current state, and future implications of promising biomedical offerings in the field of retina.
RECENT FINDINGS
The technologies discussed are some of the more recent promising biomedical developments within the field of retina. There is a US Food and Drug Administration-approved gene therapy product and artificial intelligence device for retina, with many other offerings in the pipeline.
SUMMARY
Signaling pathway therapies, genetic therapies, mitochondrial therapies, and artificial intelligence have shaped retina care as we know it and are poised to further impact the future of retina care. Retina specialists have the privilege and responsibility of shaping this future for the visual health of current and future generations.
目的综述
本文旨在回顾和讨论视网膜领域中具有前景的生物医学产品的历史、现状和未来意义。
最新发现
本文讨论的技术是视网膜领域中较为新颖的有前景的生物医学进展。目前已有一款经美国食品和药物管理局批准的视网膜基因治疗产品和人工智能设备，还有许多其他产品正在研发中。
总结
信号通路疗法、基因疗法、线粒体疗法和人工智能已经改变了我们所了解的视网膜治疗方法，并有望进一步影响视网膜治疗的未来。视网膜专家有责任和特权为当前和未来几代人的视觉健康塑造这个未来。
Zotero 插件